Fluticasone, Umeclidinium, And Vilanterol

Introduction Overview

Generic Name

fluticasone, umeclidinium, and vilanterol

Brand Name

Trelegy Ellipta

Dosage Form

oral inhalation device

Drug Class

Bronchodilator combinations

Pharmacokinetics

Absorption:
Trelegy Ellipta delivers its active components—fluticasone furoate, umeclidinium, and vilanterol—via oral inhalation, resulting in predominantly pulmonary absorption. Fluticasone furoate is a highly lipophilic corticosteroid absorbed rapidly through airway mucosa, with systemic exposure typically limited due to extensive first-pass metabolism when swallowed. Umeclidinium, a long-acting muscarinic antagonist, is also absorbed through the lungs, with minimal systemic exposure due to its low oral bioavailability. Vilanterol, a long-acting beta-2 adrenergic agonist (LABA), is rapidly absorbed through the bronchial epithelium, reaching peak plasma concentrations within minutes to an hour post-inhalation. The combined delivery via the Ellipta inhaler ensures rapid onset of bronchodilation while minimizing systemic exposure to reduce side effects.

Distribution:
Post absorption, fluticasone furoate exhibits a large volume of distribution (about 3.2 L/kg), binding extensively to plasma proteins (>99%), mostly albumin, which confines free active drug availability in systemic circulation. Umeclidinium shows moderate plasma protein binding (~89%) and widespread distribution with limited penetration across the blood-brain barrier. Vilanterol demonstrates high plasma protein binding (around 94%) and a volume of distribution approximating 183 L, indicating extensive tissue distribution, particularly in lung tissue where it exerts its pharmacodynamic effect. The distribution profiles of these agents contribute to their localization in targeted respiratory tissues and influence onset and duration of action.

Metabolism:
Fluticasone furoate is predominantly metabolized in the liver via CYP3A4-mediated oxidative pathways to inactive metabolites, with negligible active metabolites contributing to systemic activity. Similarly, umeclidinium undergoes extensive hepatic metabolism primarily via CYP2D6 and other pathways, resulting in inactive metabolites eliminated chiefly via bile. Vilanterol is metabolized extensively in the liver by CYP3A4 enzymes, yielding metabolites devoid of significant pharmacologic activity. The metabolic pathways of these agents underscore the importance of accounting for potential drug interactions mediated by CYP enzymes, particularly CYP3A4 inhibitors or inducers.

Elimination:
The elimination of fluticasone furoate occurs mainly through fecal excretion of metabolites, with less than 1% recovered unchanged in urine. Its elimination half-life supports once-daily dosing. Umeclidinium has a terminal elimination half-life of approximately 11 to 13 hours, with excretion predominantly via feces through biliary secretion. Vilanterol exhibits a half-life of about 21 hours, allowing for sustained bronchodilatory effect over 24 hours; primarily, metabolites and unchanged drug are excreted in urine and feces. Renal impairment is not expected to significantly alter elimination, whereas hepatic impairment may impact metabolism and systemic exposure, necessitating clinical consideration. Overall, the pharmacokinetic profiles of Trelegy Ellipta's components support once-daily inhalation for maintenance therapy in COPD and asthma.

Dosage Forms

Available Dosage Forms:
Trelegy Ellipta is formulated as a dry powder inhalation device, supplied in a convenient preloaded inhaler. It is available in two strengths per actuation:
1. 100 mcg fluticasone furoate / 62.5 mcg umeclidinium / 25 mcg vilanterol
2. 200 mcg fluticasone furoate / 62.5 mcg umeclidinium / 25 mcg vilanterol
Each actuation delivers these fixed doses of the combination medications. The inhaler comes in a foil tray containing a desiccant to maintain powder dryness before first use.

Dosages for Adults and Adolescents:
Trelegy Ellipta is indicated for use only in adults 18 years and older. The typical dosing regimen involves one inhalation of the selected strength once daily, preferably at the same time each day. For COPD maintenance, either dose strength may be used, with the 100 mcg fluticasone dose often preferred initially to balance efficacy and safety. Patients experiencing inadequate control may be titrated to the higher 200 mcg strength under medical supervision. For asthma maintenance treatment, dosing considerations involve evaluating disease severity and prior therapy; the 100 mcg combination may be started, with possible escalation to 200 mcg if asthma control remains suboptimal.

Specific Patient Populations:
Trelegy Ellipta has not been approved for use in pediatric patients (under 18 years of age). No dosing recommendations exist for this population. In elderly patients, no dose adjustments are typically necessary, but greater sensitivity to the drug’s effects may warrant cautious use. The drug should be used cautiously in patients with hepatic impairment due to metabolism considerations, although specific dose adjustments have not been established. It is not recommended during pregnancy or breastfeeding without medical evaluation, as safety data are limited. Patients with severe milk protein allergy should avoid Trelegy Ellipta due to lactose monohydrate excipient containing milk proteins.

Clinical guidelines emphasize adherence to once-daily dosing, caution with abrupt corticosteroid withdrawal, and patient-specific adjustments based on symptom control and exacerbation risk.

Mechanism Of Action

Trelegy Ellipta is a fixed-dose combination inhalation product containing fluticasone furoate, umeclidinium, and vilanterol, each targeting different pathways to synergistically improve respiratory function in patients with COPD and asthma.

Fluticasone furoate is a potent, synthetic inhaled corticosteroid (ICS) that exerts anti-inflammatory effects by binding to glucocorticoid receptors in airway cells. This binding modulates gene expression, resulting in decreased synthesis and release of pro-inflammatory cytokines, histamines, and leukotrienes. By suppressing airway inflammation, fluticasone reduces airway hyperreactivity, edema, and mucus production, thus improving airflow and symptom control.

Umeclidinium functions as a long-acting muscarinic antagonist (LAMA). It competitively inhibits M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction. The blockade of these receptors leads to relaxation of airway smooth muscle and sustained bronchodilation, reducing airway resistance and improving airflow in obstructive pulmonary diseases.

Vilanterol, a long-acting beta2-adrenergic receptor agonist (LABA), selectively stimulates beta2 receptors on bronchial smooth muscle cells, activating adenylate cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP leads to relaxation of airway smooth muscle and bronchodilation. Vilanterol has a prolonged duration of action allowing once-daily dosing.

Together, these three agents combine to provide complementary pharmacologic effects: fluticasone reduces airway inflammation, umeclidinium blocks parasympathetic bronchoconstriction, and vilanterol induces beta2-mediated bronchodilation. Clinical studies demonstrate that this triple therapy improves lung function, reduces exacerbations, and ameliorates symptoms more effectively than dual or monotherapy inhalers.

Comparatively, when viewed against other combination bronchodilators such as Breo Ellipta (fluticasone/vilanterol) or Anoro Ellipta (umeclidinium/vilanterol), Trelegy Ellipta’s triple pharmacologic action provides broader and enhanced control of airflow obstruction and inflammation. Research evidence from randomized controlled trials supports its efficacy and safety profile for maintenance treatment of COPD and asthma in adults. Moreover, the combination reduces the risk of vilanterol-associated mortality seen with LABA monotherapy in asthma by simultaneous administration with corticosteroid and antimuscarinic agents.

Pharmacological Actions

Anti-inflammatory action via inhaled corticosteroid (fluticasone) reduces airway edema and mucosal inflammation.
Long-acting muscarinic receptor antagonism (umeclidinium) promotes sustained bronchodilation by inhibiting acetylcholine-induced bronchoconstriction.
Long-acting beta2-adrenergic receptor agonism (vilanterol) causes smooth muscle relaxation via increased cAMP.
Synergistic triple therapy enhances lung function and symptom control in COPD and asthma.
Reduction in frequency and severity of COPD exacerbations.
Improvement in airflow, measured by FEV1 and peak expiratory flow rates.
Prevention of bronchospasm and airway hyperresponsiveness.
Maintenance of airway patency with once-daily dosing convenience.
Modulation of inflammatory mediators like cytokines and leukotrienes.
Decreased mucus production and airway remodeling.
Improved exercise tolerance and quality of life in chronic lung disease patients.
Lower systemic corticosteroid exposure compared to oral steroids due to targeted delivery.
Stabilization of airway function and prevention of disease progression.
Minimization of adverse cardiovascular effects typical of beta2 agonists when combined appropriately.
Compatible with other respiratory therapies including rescue inhalers.

Therapeutic Or Clinical Uses

Maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Reduction of COPD exacerbations in patients with a history of frequent or severe exacerbations.
Maintenance treatment of asthma in adults to prevent and control symptoms.
Improvement of lung function and reduction of airflow obstruction.
Prevention of bronchospasm in COPD and asthma patients.
Used in patients requiring triple therapy combining inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta2 agonists.
Management of moderate to severe COPD inadequately controlled with dual therapy.
Adjunct to therapy for patients with frequent exacerbations despite monotherapy or dual therapy.
Improvement in health-related quality of life by reducing symptom burden.
Suitable for once-daily dosing, enhancing patient adherence.
Alternative to separate inhalers providing combined pharmacotherapy.
Treatment option for adult patients not adequately controlled with inhaled corticosteroids and LABA alone.
Prevention of disease progression through control of airway inflammation and airflow limitation.
Not indicated for acute bronchospasm or rescue use.
Approved for adult patients only; not for pediatric use.

Side Or Adverse Effects

Upper respiratory tract infections including cold or flu-like symptoms (stuffy or runny nose, sore throat, cough).
Lung infections such as pneumonia.
Gastrointestinal symptoms including nausea, vomiting, constipation, and diarrhea.
Joint pain or arthralgia.
Oral side effects such as mouth sores, hoarseness, mouth pain, and changes in taste.
Headache and back pain.
Tremors or nervousness, particularly related to the beta2 agonist component.
Chest pain and palpitations including fast or pounding heartbeats.
Wheezing, choking, or worsening breathing difficulty after inhalation.
Oral candidiasis due to inhaled corticosteroid use.
Painful or difficult urination.
Visual disturbances including blurred vision, tunnel vision, eye pain, and seeing halos around lights.
Electrolyte disturbances such as hypokalemia with symptoms like leg cramps and muscle weakness.
Signs of elevated blood sugar (hyperglycemia) including increased thirst and urination, dry mouth, and fruity breath odor.
Possible allergic reactions with hives, swelling of face, lips, tongue, throat, or difficulty breathing.

Precautions

Not to be used for acute bronchospasm or asthma attacks; only for maintenance treatment.
Avoid sudden withdrawal from systemic corticosteroids when transitioning to Trelegy Ellipta; tapering under medical supervision is advised.
Use with caution in patients with cardiovascular disease, including arrhythmias, hypertension, and ischemic heart disease.
Monitor patients with a history of seizures or convulsive disorders.
Caution in patients with glaucoma, cataracts, or other ocular conditions; regular eye exams recommended.
Avoid in patients with severe milk protein allergy due to lactose monohydrate content.
Careful use in patients with thyroid disorders and diabetes; monitor glycemic control closely.
Risk of infections may be increased; avoid exposure to chickenpox or measles and seek prompt treatment if exposed.
Cautious use in patients with prostate enlargement or urinary retention problems.
Potential immunosuppressive effect; monitor for infections including bacterial, fungal, viral, or parasitic.
Not approved for pediatric patients under 18 years of age.
Pregnancy and breastfeeding safety not established; use only if benefits outweigh risks.
Advise patients to rinse mouth after inhalation to prevent oral thrush.
Avoid using multiple products containing long-acting beta agonists concurrently.
Careful patient education on inhaler technique is essential for effective therapy.

Warnings

Trelegy Ellipta is not a rescue medication and will not treat acute bronchospasm or asthma attacks.
Use appropriate fast-acting bronchodilators for sudden breathing problems.
Do not exceed prescribed dose—overuse increases risk of serious cardiovascular adverse effects.
Contraindicated in patients with severe hypersensitivity to milk proteins or any component of the product.
May cause paradoxical bronchospasm; discontinue therapy if this occurs and seek medical attention.
Use caution in patients with cardiovascular disorders; beta2 agonists can provoke arrhythmias or ischemia.
Long-acting beta2 agonist monotherapy in asthma may increase risk of asthma-related death; the combination with corticosteroid and LAMA mitigates this risk.
Monitor for glaucoma and cataract development with prolonged inhaled corticosteroid use.
Patients should be advised to contact their healthcare provider if breathing worsens after starting treatment.
Abrupt withdrawal of systemic corticosteroids during initiation can precipitate adrenal insufficiency; taper gradually.
Increased risk of pneumonia in COPD patients treated with inhaled corticosteroids.
Dose adjustments may be necessary in hepatic impairment due to altered metabolism.
Do not use with other LABA-containing products due to risk of overdose.
Potential for immunosuppression necessitates vigilance for infections.
Store inhaler properly; discard after 6 weeks of opening or when dose counter reaches zero.

Contraindication

Known hypersensitivity to fluticasone furoate, umeclidinium, vilanterol, or any other component in Trelegy Ellipta.
Severe allergy to milk proteins due to lactose excipient.
Use for acute treatment of bronchospasm or asthma exacerbations is contraindicated.
Do not use as monotherapy in asthma (vilanterol alone has increased mortality risk), only as part of combination therapy.
Contraindicated in patients with status asthmaticus or acute episodes requiring urgent intervention.
Known hypersensitivity to other anticholinergic or beta2 agonist medications related to umeclidinium and vilanterol respectively.
Avoid in patients with severe hypersensitivity reactions to any inhaled corticosteroids.
Not recommended for use in pediatric populations due to lack of safety and efficacy data.
Contraindicated in patients with uncontrolled cardiovascular disease where beta2 agonists could pose risk.
Do not combine with other long-acting beta agonists or muscarinic antagonists to prevent overdose.
Contraindicated in patients with severe urinary retention not manageable by concurrent treatment.
Known hypersensitivity to lactose or excipients causing intolerance reactions.
Avoid use during pregnancy and breastfeeding unless benefits clearly outweigh risks.
Contraindicated in patients with narrow-angle glaucoma or untreated severe bladder obstruction unless carefully monitored.
Contraindicated in individuals with hypersensitivity to corticosteroids manifesting as severe allergic reactions.

Drug Interactions

Concomitant use with other long-acting beta-2 agonists (e.g., salmeterol, formoterol, indacaterol) increases risk of additive cardiovascular side effects.
CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can increase systemic exposure of fluticasone and vilanterol, leading to enhanced systemic corticosteroid effects and beta agonist toxicity.
CYP3A4 inducers (e.g., rifampin, phenytoin) may decrease therapeutic efficacy by increased metabolism of fluticasone and vilanterol.
Use with anticholinergic agents (e.g., atropine, ipratropium) can potentiate antimuscarinic effects of umeclidinium, increasing risk for anticholinergic side effects.
Monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants may potentiate cardiovascular effects of vilanterol.
Beta-blockers (non-selective) can antagonize bronchodilatory effects of vilanterol; caution advised.
Concurrent use with diuretics may exacerbate hypokalemia induced by beta2 agonists.
Drugs that prolong QT interval may increase arrhythmogenic risk when combined with vilanterol.
Corticosteroids can suppress immune responses and increase risk of infections when combined with immunosuppressants or antifungal medications.
Use with other CNS-active drugs (e.g., antidepressants, antipsychotics) may enhance nervous system side effects such as tremor or anxiety.
Combination with medications for Parkinson’s disease may cause additive anticholinergic effects.
Potassium-lowering drugs or laxatives may increase risk of hypokalemia with vilanterol.
Antidepressants, antifungals, and antiviral agents metabolized by CYP3A4 may alter pharmacokinetics of components.
Careful monitoring is advised when combining with drugs for overactive bladder or irritable bowel syndrome that have anticholinergic properties.
Caution with other allergy or cold medications that can interact synergistically or antagonistically.

Preparations Of The Drug

Trelegy Ellipta available as pressurized dry powder inhaler for oral inhalation.
Delivered in a sealed foil tray containing 30 doses with built-in dose counter.
Two available dosage strengths: 100 mcg fluticasone furoate/62.5 mcg umeclidinium/25 mcg vilanterol per actuation and 200 mcg fluticasone furoate/62.5 mcg umeclidinium/25 mcg vilanterol per actuation.
Inactive ingredients include lactose monohydrate (containing milk proteins) and magnesium stearate.
Comes with patient instructions on proper inhaler use, storage, and disposal.
Packaging designed to maintain powder stability with desiccant included in foil tray.
Shelf life and stability supported at room temperature (68°F to 77°F or 20°C to 25°C) with protection from moisture and heat.
Each inhaler contains a fixed number of doses, with dose counter alerting when 10 doses remain.
Foil tray to be opened immediately before first use; inhaler discarded 6 weeks after opening or when counter reaches zero.
Device incorporates a single-step inhalation mechanism without need for shaking.
Formulated to optimize lung deposition and minimize oropharyngeal deposition.
Available only by prescription with appropriate labeling for adult COPD and asthma maintenance.
Manufactured by GlaxoSmithKline with sterile and quality-controlled production standards.
Instructions emphasize rinsing mouth after use to prevent Candida infections.
Designed for once-daily dosing regimen to simplify treatment adherence.